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44% (no clear trend), price concerns were discussed in 34% of PSD’s (increasing 
trend) and risk-share arrangements in only 2% (no clear trend). Methodology: 
Indirect comparisons were predominantly simple common-comparator type 
with Bayesian or Mixed Treatment Comparisons used in 2% and 1% of PSD’s, 
respectively. Economic models were generally Markov type. CONCLUSIONS: A 
substantial number of appraisals have been completed. The content of PBAC 
submissions has remained fairly stable over this period with the exception of 
perceived uncertainty in the clinical evidence. There has also been relatively 
little use sophisticated techniques such as Mixed Treatment Comparisons. 
Further analyses may prove useful to better understand the nature and PBAC 
interpretations of clinical evidence quality.  
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OBJECTIVES: In Europe, the shift to a value-based pricing (VBP) approach in the 
UK, Germany and France underscores the policy objective of obtaining value for 
money through formal HTA processes. The German AMNOG reform enacted in 
2011 represents a major step in standardizing the assessment and price 
negotiation procedure for new drugs. The UK also plans to implement a VBP by 
2014 with an increased role for HTA in pricing decisions. This study explores key 
policy parameters and their plausible implications. METHODS: A critical review 
of recent developments in these three HTA systems was conducted. RESULTS: 
Key parameters such as the choice of comparator will continue to be critical 
during technology assessment, as evident in recent German IQWiG/GBA 
evaluations. Subsequent negotiation processes that take into account multiple 
criteria on top of value evaluation also play an important role in German and 
French pricing decisions. Additionally, developments associated with VBP will 
likely generate new challenges in the access environment for innovative drugs. A 
prominent example is the UK government’s proposition of discontinuing 
consideration of patient access schemes which have been a major access 
mechanism for innovative products. CONCLUSIONS: The passage of AMNOG in 
Germany and upcoming VBP reform in the UK ends the era of free pricing in 
major European markets. Although there are significant uncertainties about final 
form that VBP will take in both nations, the inherent risks to the pharmaceutical 
industry cannot be ignored. While the most proximate impact from these 
structural changes will likely be pricing pressure, potential delay to market 
caused by HTA processes and price negotiations are also likely headwinds. 
Finally, these developments could generate implications beyond Western Europe 
through international reference pricing and informal policy influencing other 
markets.  
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OBJECTIVES: Pharmaceutical manufacturers routinely face the challenge of 
eroding patents of their major brands. Companies have to prepare well in 
advance for the loss of exclusivity (LoE) and this is always under the scrutiny  
of payers and shareholders alike. Entry of generics leads to substantial revenue 
losses and managing it is in some instances even more challenging  
than launching a branded product. This research is aimed at elucidating the 
policies that pharmaceutical companies need to consider as they prepare for  
LoE of their branded products. This paper also deals with the strategic aspects 
that lead to maintaining a successful product post LoE. METHODS: The research 
was conducted through in-depth secondary research and interviews with  
key stakeholders in 8 countries including the UK, Japan, France, Germany,  
Italy, Austria, Sweden and Belgium RESULTS: Analysis indicates that the 
markets react differently when a product loses patent and this is dependent  
on the policies of generic substitution, clinical training of the physicians in the 
country, prescription habits and policies, awareness of patients and more 
importantly socio economic conditions of the country. These factors lead  
to differences in the potential price and access of the branded drug post LoE in 
the different markets making it a challenging process. CONCLUSIONS:  
The research identifies the stage at which a pharmaceutical company should 
start to prepare for the LoE, the typical projects that need to be conducted and 
also the opportunities the companies have with the product. Market specific 
strategies were assessed that included policy implications of generic 
substitution, the powers of physicians and retail pharmacists in prescribing, 
substituting and dispensing respectively and how policies play a role in 
influencing the pricing and reimbursement of the product post LoE and its 
generic competitors.  
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OBJECTIVES: The German health care system is one of the world's most 
important pharmaceutical markets after the US and Japan. Its regulation has 
undergone a series of changes in the past ten years. We aim to analyze the role 
of cost-effectiveness analysis (CEA) in German pharmaceutical price regulation. 
METHODS: We analyze 7 regulatory acts from 2002 to 2011 for their impact on 
the implementation of CEA in the German health care system. We put emphasis 
on the analysis of CEA's failure during the period from 2007 to 2010. We discuss 
CEA's current role under AMNOG regulation and possible alternatives. RESULTS: 
The first attempt to establish CEA in Germany was undertaken in 2007 with the 
mandate for IQWiG to develop a method for CEA in Germany. IQWiG published 
its efficiency frontier method in 2009. IQWiG was commissioned with CEA of 
various antidepressants and clopidogrel. No analysis had been finished by the 
end of 2010. CEA was substituted by the 2011 AMNOG act. AMNOG introduced 
early benefit assessments followed by pricing negotiations for all new drugs. 
After an initial rebate agreement, both sickness funds and manufacturers can 
commission IQWiG with CEA. CEA can be based on German observational data 
for up to three years. CEA under AMNOG has no immediate effect but new rebate 
negotiations can be based on its results. CONCLUSIONS: German pharmaceutical 
pricing regulation aimed at randomly reducing pharmaceutical expenditure 
growth. Mandatory rebates, payments of solidary fees by the pharmaceutical 
industry, and price moratoriums were common elements in the past 10 years. 
The legislator failed to specify clear guidelines for the development of a method 
for CEA. The efficiency frontier method lacked acceptance among experts. Its 
first application on antidepressants took three years. CEA remained a theoretical 
option without any real-world impact by the end of 2012. Cost per QALY 
approaches remain a viable alternative.  
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OBJECTIVES: The U.S. Food and Drug Administration (FDA) assigns a “Priority 
Review” designation to drugs it believes offer substantial benefit over existing 
treatments. However, the extent to which these drugs actually provide 
additional health benefits over non-priority drugs has not been well established. 
We evaluated the incremental QALY gains of newly-approved drugs assigned a 
Priority Review designation and approved drugs without that designation. 
METHODS: We used the FDA’s website to identity drugs first approved by the 
FDA from 1993-2008 (n=474). For each drug, we used the Tufts Medical Center 
Cost-Effectiveness Analysis Registry (www.cearegistry.org) to identify pertinent 
cost-utility analyses (CUAs). We reviewed each CUA to ensure the drug was 
evaluated in accordance with the approved FDA label and that the comparator in 
the CUA was appropriate. We found 538 relevant CUAs in the Registry. We used 
multivariate regression to evaluate the relationship between incremental QALY 
gains (dependent variable) and the FDA’s Priority Review designation, adjusting 
for drug approval year and study sponsorship, i.e., whether the study was 
industry-funded. The model was adjusted for multiple ratios and multiple CUAs 
for a drug. RESULTS: Of the 474 newly approved drugs included in our sample, 
192 (40.5%) were assigned a Priority Review designation by the FDA. Drugs 
designated as priority review were associated with an increase in incremental 
QALY gains (0.311; p<0.05), after adjusting for study sponsorship and drug 
approval year. CONCLUSIONS: Drugs designated for Priority Review by the FDA 
showed increased QALY gains relative to approved drugs without this 
designation. These findings suggest that the FDA actions have been appropriate 
in applying the Priority Review designation to newly-approved drugs, in that 
these drugs offer substantial benefit over existing treatments compared to the 
benefits provided by non-priority drugs.  
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OBJECTIVES: Although it is not explicitly the role of NICE to assess the 
implementation of its guidance, a repository of guidance-specific uptake reports 
has been developed. These reports aim to analyse the uptake activity and 
national trends across the UK associated with NICE recommendations. The 
objective of this study was to assess all NICE implementation uptake reports in 
order to evaluate whether the recommendations from NICE are correlated with 
uptake in real clinical practice. METHODS: Thirty-one uptake reports were 
analysed, and it was recorded whether they related to NICE clinical guidelines or 
technology appraisals and how the true uptake of guidance related to the initial 
forecast provided by NICE. RESULTS: Of the 31 uptake reports, 13 and 17 related 
to clinical guidelines and technology appraisals, respectively. One report 
pertained to both a clinical guideline and a technology appraisal. Of the 31 
reports studied, 3 indicated that the level of uptake was higher than that 
projected by NICE, 16 were consistent with the direction anticipated by NICE, and 
2 indicated that uptake was lower than that forecasted. A further 2 reports 
indicated significant variability in the predicted trajectory of implementation. 
Due to the breadth and complexity of the guidelines, it could not be inferred 
from 8 reports whether national trends and uptake activity were in line with 
NICE recommendations (of which 5 pertained to clinical guidelines). Of the 3 
uptake reports indicating that uptake was higher than anticipated, 2 related to 
the pharmacological management of type II diabetes. Another uptake report for 
laparoscopic surgery described greater levels of uptake than expected. 
CONCLUSIONS: Generally, guidance from NICE is strongly associated with the 
implementation of the technology in clinical practice. However, in some cases 
implementation was variable to what had been projected by NICE and in others 
it was impossible to measure uptake.  
